ERCC1 and gastric cancer: ERCC1 helps repair DNA damage caused by platinum-based therapy: its low expression is associated with longer survival in advanced colorectal cancer treated with 5-fluorouracil/oxaliplatin while its high expression is associated with response to irinotecan therapy.(31) Among gastric cancer patients, those treated with a FOLFOX (5-fluorouracil/leucovorin/oxaliplatin) regimen or first-line cisplatin-based regimens respond significantly better if they show lower levels of ERCC1 expression.(32) Low ERCC1 is also a favorable indicator for response to platinum therapy in lung cancer.(25)